Sorrento Therapeutics, Inc. (NASDAQ:SRNE) shares are trading higher after the company announced its STI-4398 demonstrated ability in preclinical studies to completely inhibit the Sars-Cov-2 viral infection in vitro.
Sorrento Therapeutics is a clinical-stage biopharma company that develops therapies for cancer, autoimmune, inflammatory, and neurodegenerative diseases.
Sorrento's shares were up 7.77% at $4.16 per share on Friday at the time of publication. The company has a 52-week high of $10.00 and a 52-week low of $1.39.
Related Links:
Sorrento Therapeutics Has $4B Coronavirus Opportunity, Analyst Says
Revisiting The Coronavirus Vaccine Race: Updates On The 10 Candidates In Clinics
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
